Clinical Trials

New discoveries in Tang lab have been actively translated to the clinic to improve the treatment for cancer patients. Currently, there are five on-going IIT clinical trials of CAR-T cell therapy developed by Tang lab. So far, the clinical results have been reported as an oral presentation in Late-Breaking Research Minisymposium at AACR 2024,  an oral presentation in Late-Breaking Abstracts II at ASGCT 2024, an oral presentation at EHA 2024, a poster at the Society of Hematologic Oncology (SOHO) 2024, an oral presentation and a poster at the ASH 2024, an oral presentation at SOHC 2024, and an oral presentation at ESMO Immuno-Oncology Congress 2024.

DiseaseStatusClinical Trial Registration
r/r B-ALLRecruitingNCT05747157
r/​r DLBCLRecruitingNCT05715606
r/​r DLBCLRecruitingNCT06120166
r/r CD19-positive B cell Hematological MalignanciesRecruitingNCT06277011
r/r CD19-positive B cell Hematological Malignancies (6 Months to 18 Years)RecruitingNCT06393335
Moderate to Severe Active Systemic Lupus Erythematosus (SLE)Recruiting NCT06711146
r/​r B-cell Non-Hodgkin lymphomaRecruitingNCT06716164

Disclosure: Prof. Li TANG is an inventor of related patents. He is a co-founder, shareholder and advisor of Leman Biotech, a spin-off start-up biotech company from EPFL. The interests of L.T. were reviewed and managed by EPFL.

Any inquiries regarding the on-going clinical trials should be addressed to [email protected].